ReviewInternal medicine journal2025
Advancements in multiple sclerosis.
Review in Internal medicine journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Relapse prediction and individualized treatment-effect modeling in relapsing multiple sclerosis: a systematic review.Frontiers in public health · 2026Pooled it
- Sex- and age-specific associations ofAnnals of medicine · 2026Article
- Difficult relationships between humans and bacteria: associations between multiple sclerosis and the human microbiome.Antonie van Leeuwenhoek · 2026Review
- Emerging therapeutic strategies in multiple sclerosis: a focus on innovative and targeted approaches.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Immune reconstitution and tolerance-inducing therapies as promising therapeutic approaches in multiple sclerosis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Review
- Immune-cell-guided nanozymes: redefining targeted therapy for neuroinflammation in multiple sclerosis.Annals of medicine and surgery (2012) · 2026Article
- The relationship between depression, anxiety, and disability in patients with multiple sclerosis: A cross-sectional study from western Iran.PCN reports : psychiatry and clinical neurosciences · 2026Article
- Challenges and Insights in Patch-Clamp Studies: From Cell-Attached to Whole-Cell Configurations.Current issues in molecular biology · 2026Review
- Cladribine use for multiple sclerosis with autoimmune comorbidities: retrospective analysis of the French MS registry, case series, and therapeutic considerations.Therapeutic advances in neurological disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global prevalence of multiple sclerosis (MS) is increasing, and early diagnosis and treatment is essential in mitigating disability. While recent therapeutic advancements have significantly reduced relapse rates, the progressive and degenerative aspects of MS continue to pose major challenges. This year updates to the McDonald diagnostic criteria aim to enhance sensitivity and facilitate earlier use of disease-modifying therapies in asymptomatic patients. Additionally, novel biomarkers will gain ground in clinical practice and offer new approaches to optimising care. Following the widespread use of cell depleting immunosuppressive agents, innovative therapeutic directions such as chimeric antigen receptor T-cell therapy and Epstein-Barr virus (EBV) vaccination represent promising new directions in the management of MS. This clinical perspective provides a comprehensive overview of the disease while highlighting important advancements shaping the future of the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.